X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will advance research and development and clinical trial expenses of company's pipeline including LP352 (bexicaserin), an oral, centrally acting, 5-HT2C superagonist for seizures associated with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor
Deal Size: $241.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 08, 2024
Details:
The net proceeds will advance research and development expenses, clinical trial expenses of company's pipeline including LP352, an oral, centrally acting, 5-HT2C superagonist in development for seizures associated with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
The net proceeds will advance research and development expenses, clinical trial expenses of company's pipeline including LP352, an oral, centrally acting, 5-HT2C superagonist in development for seizures associated with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 02, 2024
Details:
LP352 (Bexicaserin) is a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist, which is under phase 1/2 clinical development for the treatment of Developmental and Epileptic Encephalopathies (DEEs).
Lead Product(s): Bexicaserin
Therapeutic Area: Rare Diseases and Disorders Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
LP352 (Bexicaserin) is a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist, which is under phase 1/2 clinical development for the treatment of Developmental and Epileptic Encephalopathies (DEEs).
Lead Product(s): Bexicaserin
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
